Clinical trials
Recurrence trials in Singapore
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Active, not recruiting | 5 |
| Recruiting | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| National University Hospital, Singapore | 4 |
| Bristol-Myers Squibb | 2 |
| KK Women's and Children's Hospital | 2 |
| National Cancer Centre, Singapore | 2 |
| AbbVie | 1 |
| Bayer | 1 |
| Celgene | 1 |
| CytoMed Therapeutics Pte Ltd | 1 |
| Eisai Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 28 |
| Multiple Myeloma | 7 |
| Neoplasms | 4 |
| Epstein-Barr Virus Infections | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Nasopharyngeal Carcinoma | 2 |
| Nasopharyngeal Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Neoplasms, Plasma Cell | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.